160 related articles for article (PubMed ID: 34225753)
21. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Baris HE; Anderson E; Sozeri B; Dedeoglu F
Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
[TBL] [Abstract][Full Text] [Related]
22. Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomes.
Tanatar A; Akgün Ö; Çağlayan Ş; Bağlan E; Otar Yener G; Öztürk K; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
Expert Opin Biol Ther; 2023 Mar; 23(3):305-313. PubMed ID: 36825474
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
24. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.
Erkens RGA; Calis JJA; Verwoerd A; De Roock S; Ter Haar NM; Den Engelsman G; Van der Veken LT; Ernst RF; Van Deutekom HWM; Pickering A; Scholman RC; Jansen MHA; Swart JF; Sinha R; Roth J; Schulert GS; Grom AA; Van Loosdregt J; Vastert SJ
Arthritis Rheumatol; 2024 Jan; 76(1):119-129. PubMed ID: 37471469
[TBL] [Abstract][Full Text] [Related]
25. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis.
Sura A; Failing C; Sturza J; Stannard J; Riebschleger M
Pediatr Rheumatol Online J; 2018 Jan; 16(1):2. PubMed ID: 29304824
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
27. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
28. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
31. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
Ringold S; Weiss PF; Beukelman T; DeWitt EM; Ilowite NT; Kimura Y; Laxer RM; Lovell DJ; Nigrovic PA; Robinson AB; Vehe RK;
Arthritis Rheum; 2013 Oct; 65(10):2499-512. PubMed ID: 24092554
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
33. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
34. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Beukelman T; Xie F; Baddley JW; Chen L; Mannion ML; Saag KG; Zhang J; Curtis JR
Arthritis Res Ther; 2016 Sep; 18(1):210. PubMed ID: 27655411
[TBL] [Abstract][Full Text] [Related]
35. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
36. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
37. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.
Anink J; Prince FH; Dijkstra M; Otten MH; Twilt M; ten Cate R; Gorter SL; Koopman-Keemink Y; van Rossum MA; Hoppenreijs EP; van Suijlekom-Smit LW
Rheumatology (Oxford); 2015 Nov; 54(11):1964-9. PubMed ID: 26078219
[TBL] [Abstract][Full Text] [Related]
38. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
Huang Z; Lee PY; Yao X; Zheng S; Li T
Pediatrics; 2019 May; 143(5):. PubMed ID: 30948682
[TBL] [Abstract][Full Text] [Related]
40. Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis.
George MD; Sauer BC; Teng CC; Cannon GW; England BR; Kerr GS; Mikuls TR; Baker JF
J Rheumatol; 2019 Apr; 46(4):343-350. PubMed ID: 30275262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
